# Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer

> **NCT05455619** · PHASE1,PHASE2 · RECRUITING · sponsor: **SynDevRx, Inc.** · enrollment: 52 (estimated)

## Conditions studied

- HR+/HER2-negative Breast Cancer
- Metastatic Breast Cancer

## Interventions

- **DRUG:** Evexomostat

## Key facts

- **NCT ID:** NCT05455619
- **Lead sponsor:** SynDevRx, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-08-26
- **Primary completion:** 2026-12
- **Final completion:** 2027-03
- **Target enrollment:** 52 (ESTIMATED)
- **Last updated:** 2026-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05455619

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05455619, "Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05455619. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*